Oculus Innovative Sciences (OCLS) – Company Press Releases
-
CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
-
Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
-
Oculus Innovative Sciences Announces Corporate Name Change to Sonoma Pharmaceuticals, Inc. and New NASDAQ Ticker Symbol to Better Align with Dermatology Focus
-
Oculus Innovative Sciences One Ups Itself, Meets Expectations Yet Again -- SECFilings.com
-
Oculus Innovative Sciences Reports Financial Results for Fiscal Second Quarter 2017
-
Oculus Innovative Sciences Sells Latin America Business to Invekra S.A.P.I. de C.V. for $19.5 Million in Cash
-
Oculus Innovative Sciences Announces Fiscal Second Quarter 2017 Financial Results and Conference Call
-
Oculus Innovative Sciences Launches Lasercyn™ into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
-
Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms
-
SECFilings.com: Oculus Innovative Sciences (OCLS) Tackling Eczema From the Inside Out and Outside In
-
Oculus Innovative Sciences Receives Australian Approvals to Market Sterile Microcyn®-Based Antimicrobial Solutions and Hydrogel Dressings
-
SECFilings.com: OCLS Keeping in Step With Innovation and US Dermatology Market Penetration
-
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017
-
Oculus Innovative Sciences Announces Fiscal First Quarter 2017 Financial Results and Conference Call
-
Oculus Innovative Sciences Announces Record Monthly and Quarterly Prescription Data
-
SECFilings.com Examines Oculus Innovative Sciences' Financial Results and Turnaround Plan
-
Oculus Innovative Sciences Announces Reverse Split of Common Stock
-
Oculus Innovative Sciences Reports Financial Results for Fiscal Year 2016 and Fourth Quarter Ending March 31, 2016
-
Oculus Innovative Sciences Announces Financial Results for the Fiscal Year/Fourth Quarter 2016 and Conference Call
-
Oculus Innovative Sciences Launches New Ceramax™ Skin Barrier Cream in the United States
-
Oculus Innovative Sciences to Present at Pioneers 2016 Investor Conference Hosted by Joseph Gunnar & Company in New York City
-
Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
-
Oculus Innovative Sciences Receives U.S. FDA Approval for Lasercyn™ for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
-
Oculus Innovative Sciences Receives European Approval to Market Sinudox™ Indicated for Use in Nasal Irrigation
-
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of New Patents for Microcyn® Technology
-
Oculus Innovative Sciences and Lipogrid of Sweden Announce Strategic Collaboration for Topical Dermatology Drug Delivery
-
Oculus Innovative Sciences to Present at the Sidoti Emerging Growth Conference
-
Oculus Innovative Sciences Announces Multi-Year Licensing Agreement with Manna Pro Products, LLC, for MicrocynAH® Animal Healthcare Products
-
Oculus Innovative Sciences Announces Pricing of $3.4 Million Underwritten Public Offering
-
Oculus Innovative Sciences Announces Proposed Underwritten Public Offering of Common Stock and Warrants
-
Oculus Innovative Sciences to Present at the Roth Capital Partners 28th Annual Conference
-
Oculus Innovative Sciences Receives European Approval to Market Lasercyn Indicated for Use Following Laser Skin Resurfacing
-
Maxim Group Hosts Key Opinion Leaders Discussing “Breakthroughs in Dermatology” Relating to Products From Oculus Innovative Sciences
-
Oculus Innovative Sciences to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
-
Oculus Innovative Sciences Reports Third Quarter Financial Results
-
Oculus Innovative Sciences Announces Fiscal Third Quarter 2016 Financial Results and Conference Call
-
Oculus Innovative Sciences Receives European CE Mark for New MucoClyns™ for First Responders
-
Oculus Innovative Sciences Receives FDA Clearance for Microcyn®-Based SebDerm Gel
-
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2016
-
Oculus Innovative Sciences Announces Fiscal Second Quarter 2016 Financial Results and Conference Call
-
Oculus Innovative Sciences Introduces MicrocynAH(R) Next-Generation Dermatology Products With Dimethicone for Animals
-
Oculus Innovative Sciences Announces Preliminary Results for Its 2015 Annual Meeting of Stockholders
-
Oculus Innovative Sciences Announces Introduction of Alevicyn SG Antipruritic Spray Gel for Relief of Pain and Itch in Atopic Dermatitis
-
Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016
-
Oculus Innovative Sciences Announces Fiscal First Quarter 2016 Financial Results and Conference Call
-
Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
-
Oculus Innovative Sciences Receives New U.S. Patent for Microcyn(R) Technology in Treatment of Atopic Dermatitis
-
Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule
-
Oculus Innovative Sciences Announces Sale of 1.65 Million Shares of Ruthigen Stock for $4.5 Million in Non-Dilutive Funding
-
Oculus Innovative Sciences Reports Financial Results for the Fourth Quarter of Fiscal Year 2015
Back to OCLS Stock Lookup